Invetx,You can find more information at BostonPioneer, MA-based in$60.5m was raised for protein-based therapies for animal health in Series B financing.
TheF- led roundPrime Capital, Novo HoldingsGV (previously Google Ventures() Eight RoadsParticipation from existing investors Anterra Capital, Casdin CapitalFunds managed by Tekla Capital Management, LLC.
TheCompany plans to use the funds in order to expand its monoclonal antibody pipeline (mAb) and pursue market approvals for therapeutics that target serious and chronic diseases. inBoth cats and dogs.
LedBy Juergen HornDr., chief executive officer. InvetxIt has developed an integrated, iscovery-, development- and manufacturing platform to create species-specific, optimized, and half-life extended product candidate candidates. ByExploiting validated biotechnologies derived from human health and optimizing for their application inThe company can create differentiated antibodies to treat a wide range of chronic and severe diseases. in animals. InvetxA wide range of biotherapeutics are in its pipeline inMultiple therapeutic areas, and hopes to advance multiple candidates inPotential product approvals could be achieved as soon as 2025. InThe company also has a partnership for discovery, development and commercialization. Boehringer Ingelheim to pursue novel programs inIn addition to its own product range. InvetxAbCellera has also expanded its collaborations Twist Bioscience Wuxi Biologics.